2021年丁型肝炎病毒:病毒学、免疫学及难治性疾病的新治疗策略
约5%的乙肝病毒感染者合并丁肝病毒感染,慢性共感染预后不良,多在5-10年内进展为肝硬化、肝衰竭或肝细胞癌。近年鉴定HBV/HDV受体并建立体外和动物感染模型,促进特异性抗病毒药物研发;同时表征HDV特异性CD4+和CD8+T细胞表位,为免疫治疗策略奠定基础。聚乙二醇干扰素α用于HDV治疗已30年但持续应答有限,本文描述新治疗方案的作用机制和临床有效性。
要点
- 约5%的HBV感染者合并HDV感染,慢性共感染5-10年内可进展为肝硬化、肝衰竭或肝细胞癌。
- 新模型和表位鉴定促进特异性药物及免疫治疗策略开发。
- bulevirtide于2020年获EU有条件上市许可,lonafarnib在III期试验中。
核心结论
- HDV病毒学、免疫学和治疗的最新进展使HDV成为不再那么难治的病毒。
研究设计与样本
- 本文为综述,描述HDV新治疗选项的作用机制和临床有效性。
主要发现
- 约5%的HBV感染者合并HDV感染,慢性共感染5-10年内可致肝硬化、肝衰竭和肝细胞癌。
- 鉴定HBV/HDV受体并建立体外和动物感染模型,促进特异性抗病毒药物开发。
- 表征未治疗和治疗患者中HDV特异性CD4+和CD8+T细胞表位,可能为免疫治疗策略铺路。
- 聚乙二醇干扰素α治疗HDV已30年,仅有限持续应答。
- bulevirtide于2020年获EU有条件上市许可,lonafarnib在III期临床试验中。
临床怎么用
- bulevirtide(Hepcludex)已于2020年获EU有条件上市许可用于HDV治疗。
- lonafarnib正在III期临床试验中研究。
- REP2139Ca等策略靶向乙型肝炎表面抗原。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5-10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific therapies targeting viral or host factors. Pegylated interferon-α has been used for treating HDV patients for the last 30 years with only limited sustained responses. Here we describe novel treatment options with regard to their mode of action and their clinical effectiveness. Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex). One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.
引用
- Urban S, Neumann-Haefelin C, Lampertico P, et al. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021. PMID: 34103404. doi:10.1136/gutjnl-2020-323888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。